

This listing of claims replaces all prior versions and listings of claims in this application.

**LISTING OF CLAIMS:**

F1  
Claim 1 (Previously Presented): A tablet comprising crystals of a pharmaceutically acceptable salt of citalopram, wherein the median particle size of the crystals is at least 40  $\mu\text{m}$ , which is prepared by direct compression of the pharmaceutically acceptable salt and pharmaceutically acceptable excipients.

Claims 2-3 (Canceled)

2  
Claim 4 (Previously Presented): The tablet according to claim 1 which does not contain a binder.

3  
Claim 5 (Previously Presented): The tablet according to claim 1 which contains 2-60% w/w active ingredient calculated as citalopram base.

4  
Claim 6 (Previously Presented): The tablet according to claim 1 which contains a filler selected from lactose, sugars, calcium phosphates, starch, modified starches, microcrystalline cellulose, calcium sulfate and calcium carbonate.

5  
Claim 7 (Previously Presented): The tablet according to claim 6, wherein the filler is a microcrystalline cellulose.

6  
Claim ~~8~~ (Previously Presented): The tablet according to claim 1 which contains a lubricant selected from metallic stearates, stearic acid, wax, hydrogenated vegetable oil, tlc and colloidal silica.

7  
Claim ~~9~~ (Previously Presented): The tablet according to claim ~~8~~, wherein the lubricant is magnesium stearate or calcium stearate.

8  
Claim ~~10~~ (Previously Presented): The tablet according to claim 1 which is substantially free of lactose.

F1  
CONT.  
Claim 11 (Canceled)

9  
Claim ~~12~~ (Previously Presented): The tablet according to claim 1 wherein the pharmaceutically acceptable salt is citalopram hydrobromide or citalopram hydrochloride.

10  
Claim ~~13~~ (Previously Presented): The tablet according to claim ~~12~~, wherein the pharmaceutically acceptable salt is citalopram hydrobromide.

Claims 14-35 (Canceled)

11  
Claim ~~36~~ (Previously Presented): The tablet of claim 1, which contains 10-40% w/w active ingredient calculated as citalopram base.

12  
Claim ~~37~~ (Previously Presented): The tablet of claim 1, which contains 15-25% w/w active ingredient calculated as citalopram base.

{M:\5432\0i004\00057402.DOC [REDACTED] }  
U.S. Patent Application Serial No. 09/730,380  
Amendment

Docket No.: 5432/01004  
Page 3

13  
Claim ~~38~~ (Previously Presented): The tablet of claim ~~6~~<sup>4</sup>, wherein said filler is a sugar selected from the group consisting of sorbitol, mannitol, dextrose and sucrose.

14  
Claim ~~39~~ (Previously Presented): The tablet of claim ~~6~~<sup>4</sup>, wherein said filler is a calcium phosphate selected from the group consisting of dibasic, tribasic, hydrous and anhydrous calcium phosphate.

15  
Claim ~~40~~ (Previously Presented): The tablet of claim ~~8~~<sup>6</sup>, wherein said lubricant is a metallic stearate selected from the group consisting of magnesium, calcium and sodium stearate.

16  
Claim ~~41~~ (Previously Presented): The tablet of claim 1, wherein the crystals have a median particle size of 40-200  $\mu\text{m}$ .

17  
Claim ~~42~~ (Previously Presented): The tablet of claim 1, wherein the crystals have a median particle size of 45-150  $\mu\text{m}$ .

18  
Claim ~~43~~ (Previously Presented): The tablet of claim 1, wherein the crystals have a median particle size of 50-100  $\mu\text{m}$ .

Claims 44-92 (Canceled)